MX2013005165A - Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico. - Google Patents

Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico.

Info

Publication number
MX2013005165A
MX2013005165A MX2013005165A MX2013005165A MX2013005165A MX 2013005165 A MX2013005165 A MX 2013005165A MX 2013005165 A MX2013005165 A MX 2013005165A MX 2013005165 A MX2013005165 A MX 2013005165A MX 2013005165 A MX2013005165 A MX 2013005165A
Authority
MX
Mexico
Prior art keywords
alkoxyimidazol
carboxylic acid
crystalline forms
biphenyl carboxylic
ylmethyl
Prior art date
Application number
MX2013005165A
Other languages
English (en)
Spanish (es)
Inventor
Paul R Fatheree
Venkat R Thalladi
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MX2013005165A publication Critical patent/MX2013005165A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013005165A 2010-11-10 2011-11-09 Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico. MX2013005165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41201110P 2010-11-10 2010-11-10
PCT/US2011/059895 WO2012064807A1 (en) 2010-11-10 2011-11-09 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Publications (1)

Publication Number Publication Date
MX2013005165A true MX2013005165A (es) 2013-07-05

Family

ID=45003086

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005165A MX2013005165A (es) 2010-11-10 2011-11-09 Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico.

Country Status (19)

Country Link
US (3) US8362060B2 (cg-RX-API-DMAC10.html)
EP (1) EP2638017B1 (cg-RX-API-DMAC10.html)
JP (2) JP2013542258A (cg-RX-API-DMAC10.html)
KR (1) KR20130130730A (cg-RX-API-DMAC10.html)
CN (1) CN103189362B (cg-RX-API-DMAC10.html)
AR (1) AR083828A1 (cg-RX-API-DMAC10.html)
AU (1) AU2011326622B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013011715A2 (cg-RX-API-DMAC10.html)
CA (1) CA2812598A1 (cg-RX-API-DMAC10.html)
CO (1) CO6741224A2 (cg-RX-API-DMAC10.html)
ES (1) ES2567721T3 (cg-RX-API-DMAC10.html)
IL (1) IL225303A0 (cg-RX-API-DMAC10.html)
MX (1) MX2013005165A (cg-RX-API-DMAC10.html)
NZ (1) NZ609804A (cg-RX-API-DMAC10.html)
PH (1) PH12013500945A1 (cg-RX-API-DMAC10.html)
RU (1) RU2013126403A (cg-RX-API-DMAC10.html)
SG (1) SG189448A1 (cg-RX-API-DMAC10.html)
TW (1) TW201300366A (cg-RX-API-DMAC10.html)
WO (1) WO2012064807A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
CN117769540A (zh) * 2021-05-11 2024-03-26 亚士德制药公司 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
TWI545114B (zh) 2009-09-29 2016-08-11 施萬生物製藥研發Ip有限責任公司 製備聯苯基咪唑化合物之方法
US8399501B2 (en) * 2010-03-04 2013-03-19 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof

Also Published As

Publication number Publication date
US20130267573A1 (en) 2013-10-10
CN103189362B (zh) 2015-03-11
IL225303A0 (en) 2013-06-27
US8362060B2 (en) 2013-01-29
JP2013542258A (ja) 2013-11-21
CA2812598A1 (en) 2012-05-18
US9249105B2 (en) 2016-02-02
BR112013011715A2 (pt) 2017-10-31
US8802709B2 (en) 2014-08-12
SG189448A1 (en) 2013-05-31
HK1187919A1 (zh) 2014-04-17
RU2013126403A (ru) 2014-12-20
US20150133518A1 (en) 2015-05-14
AU2011326622B2 (en) 2014-12-18
JP2016028061A (ja) 2016-02-25
WO2012064807A1 (en) 2012-05-18
EP2638017B1 (en) 2016-01-27
EP2638017A1 (en) 2013-09-18
NZ609804A (en) 2015-02-27
CO6741224A2 (es) 2013-08-30
ES2567721T3 (es) 2016-04-26
AR083828A1 (es) 2013-03-27
PH12013500945A1 (en) 2013-07-08
US20120115920A1 (en) 2012-05-10
TW201300366A (zh) 2013-01-01
AU2011326622A1 (en) 2013-04-04
CN103189362A (zh) 2013-07-03
KR20130130730A (ko) 2013-12-02

Similar Documents

Publication Publication Date Title
UY39646A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CR20140554A (es) Compuestos de acido dimetil-benzoico
CL2013001282A1 (es) Sal succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico; composicion farmaceutica que la comprende y procesos para su preparacion.
MX2020010330A (es) Proceso para preparar un compuesto antiviral de formula i.
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
MX2019003738A (es) Compuestos antivirales.
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
UY31770A1 (es) Inhibidores de catepsina c
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
BR112014018756A8 (pt) Processo para preparo de etil éster de ácido n-(4-ciclo-hexil-3-trifluorometil-benziloxi)-acetimídico
DOP2014000048A (es) Composiciones farmacéuticas que comprenden un polisacárido y un inhibidor hdac
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
SV2012004235A (es) Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
CO6660462A2 (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
EA201391265A1 (ru) Амиды индолкарбоновых и бензимидазолкарбоновых кислот в качестве инсектицидов и акарицидов
CL2013002129A1 (es) Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras.
CL2017002304A1 (es) Métodos para tratar enfermedades
CU24293B1 (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
CO6351775A2 (es) Forma cristalina de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
GT201200328A (es) Intermedios de agomelatina y método de preparación de éstos
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.